Moneycontrol PRO
Upcoming Event : Register for INTRAZON 3.0 India's Largest Retail Intraday Traders Online Conference

Hold Alembic Pharma; target of Rs 625: ICICI Direct

ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 625 in its research report dated November 14, 2022.

November 23, 2022 / 02:49 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Alembic Pharma

Alembic Pharma operates in international generics (US:31% & exUS: 15% in FY22), domestic branded (36% in FY22) and API (18% in FY22). Domestic business has 1.5% of market share of IPM with three brands in the top 300. Going ahead, emphasis is on the specialty segment • The company has invested ~ Rs 1800 crore in recent years in facilities geared mainly towards US formulations. As of Q2FY23, it has filed 242 ANDA and has 170 approvals with 115 launches in the US.


We upgrade from Reduce to HOLD but maintain neutral stance as we await traction rom the US focused facilities (F2, F3)), which received three USFDA product approvals (plant approvals pending) amid significant cash burn. We also keep tabs on consistency in India formulations performance. Valued at Rs 625 i.e. 30x P/E on FY24E EPS of Rs 20.8.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Alembic Pharma - 14 -11-2022 - icici

Broker Research
first published: Nov 23, 2022 02:49 pm